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Riassunto  
 
La leucemia mieloide cronica (LMC) è un disordine neoplastico della linea mieloide 
caratterizzato da una singola alterazione genetica, il gene di fusione BCR/ABL, che 
si origina a seguito di una traslocazione bilanciata tra i cromosomi 9 e 22 e che 
codifica per un proteina ad attivita’ tirosin chinasica costitutivamente attivata [1-3]. 
Attualmente, l’unico trattamento capace di eradicare in maniera definitiva questa 
malattia è il trapianto di midollo allogenico, con piu’ del 70% di successo nei pazienti 
in fase cronica [44]. Tuttavia, alcune limitazioni come la mancanza di donatori 
compatibili o l’eta’ avanzata del paziente non rendono sempre possibile questa 
metodica. 
Per questa ragione, è stato necessario sviluppare possibili vie alternative. Per piu’ di 
15 anni molti dei pazienti con LMC sono stati trattati con interferone-alfa (INF) 
capace di indurre  remissione citogenetica in piu’ del  30% dei casi. 
Successivamente, la scoperta del ruolo chiave dell’oncoproteina Bcr/Abl, 
costitutivamente attivata nella patogenesi, ha indirizzato verso una  terapia mirata 
che ha portato allo sviluppo di una serie di specifici inibitori. Il capostipite di questa 
classe di molecole è rappresentato dall’imatinib (anche conosciuto come Glivec o 
STI571), un inibitore di tipo competitivo delle tirosin chinasi di classe III, che agisce 
legandosi selettivamente al sito catalitico della proteina chimerica  Bcr/Abl, 
inibendola [46-48].  L’introduzione di questo farmaco ha segnato una profonda svolta 
nella cura della LMC ed oggi rappresenta il farmaco di prima linea per la cura di 
questa patologia. Studi clinici hanno dimostrato che il trattamento con imatinib è in 
grado di indurre una risposta citogenetica completa in piu’ dell’80% di nuove diagnosi 
di LMC. Nonostante la sua introduzione abbia segnato una rivoluzione nella terapia 
mirata contro la LMC, una parte di pazienti in fase cronica e molti di più in fase 
avanzata mostrano resistenza primaria al farmaco o sviluppano una resistenza 
secondaria durante il trattamento [51]. Possiamo distinguere tra due tipi di 
resistenza, una correlata direttamente a Bcr/Abl ed una indipendente da questo. Tra i 
meccanismi molecolari di resistenza all’imatinib Bcr/Abl dipendenti, i piu’ frequenti e 
meglio descritti sono sicuramente le mutazioni puntiformi a carico del dominio 
chinasico di Abl che limitano o impediscono al farmaco di legare ed inibire 
l’oncoproteina [66-72]. Un altro comune meccanimo di resistenza è rappresentato 
dall’overespressione della stessa proteina Bcr/Abl che richiede una maggiore 
concentrazione  intracellulare di farmaco per una sua completa inibizione [54,74]. Vi 
sono poi meccanismi indipendenti dall’oncoproteina quali l’aumento dell’espressione 
di geni come MDR1 che codifica per la glicoproteina P (Pgp), una pompa di 
membrana, che agisce espellendo in maniera dinamica il farmaco, limitandone la 
concentrazione intracellulare [55,58,75-77]. Altri meccanismi indipendenti da 
BCR/ABL e di piu’ recente scoperta sono l’overespressione di alcune proteine 
appartenenti alla famiglia delle Src chinasi come Lyn e Hck [64-65]. Nonostante i 
notevoli passi fatti a proposito, molti restano ancora i punti da chiarire sui complessi 
meccanismi molecolari che sono alla base della resistenza. Lo scopo del mio 
progetto di dottorato è stato proprio lo studio delle complesse vie intracellulari di 
trasduzione del segnale e l’espressione genica coinvolta nei meccanismi di 
resistenza all’imatinib, indipendenti da BCR/ABL. A tale scopo, abbiamo prima 
utilizzato un sistema modello ideale ed i dati cosi’ ottenuti sono stati traslati sui 
pazienti. Il sistema modello scelto da noi è rappresentato da una coppia di linee 
cellulari, le KCL22, isolate da un paziente affetto da LMC. In particolare, una linea, le 
KCL22s, risulta sensibile al trattamento con l’inibitore, mentre un’altra, le KCL22r, è 
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stata isolata come subclone dalla parentale linea sensibile dal gruppo della 
professoressa Junia Melo dell’Imperial College di Londra che collabora in questo 
progetto, e che c’è l’ha gentilmente fornita. Il sistema sperimentale delle linee Kcl22 è 
molto interessante per due motivi: nessuno dei meccanismi di resistenza ad oggi 
conosciuti vi sono stati individuati; inoltre anche la linea sensibile è intrinsecamente 
resistente al farmaco in quanto questo induce arresto della crescita cellulare, piu’ che 
apoptosi ed ha quindi un comportamento simile a quello postulato per le cellule 
staminali Ph+ [55]. In studi preliminari, combinando un approccio di natura 
proteomica ad uno di “gene profile”, abbiamo identificato una serie di geni e proteine 
differenzialmente espressi tra le due linee. Tra questi abbiamo focalizzato la nostra 
attenzione sulla tirosin fosfatasi non recettoriale SHP-1. Mediante real time PCR e 
western blot abbiamo riscontrato bassi livelli di SHP-1 sia a livello di trascritto che di 
proteina nella linea resistente KCL22r quando confrontata con quella sensibile 
KCL22s [Fig.7]. SHP-1 è altamente espressa nelle cellule della linea ematopoietica 
mentre i suoi livelli di espressione risultano piu’ bassi in altri tipi cellulari [26]. 
Nell’uomo, riduzione dell’espressione di questo gene sono stati osservati in linfomi e 
altri tipi di leucemie [82-83]. Inoltre, ridotti livelli di SHP-1 sembrano essere associati 
con la progressione della malattia dalla fase cronica a quella accelerata nella LMC 
[85]. Shp-1 e stata anche mostrata essere fisicamente associata con Bcr/Abl con 
conseguenti risvolti funzionali [86-87]. Recenti studi hanno evidenziato che SHP-1 
risulta assente nella linea cellulare di leucemia mieloide cronica in crisi bastica K562, 
e che la sua riespressione è stata accompagnata  dal differenziamento di queste 
cellule [87-88]. Inoltre, l’overespressione di Shp-1 blocca la trasformazione 
neoplastica indotta da Bcr/Abl [89]. Tutte queste osservazione sembrano indicare 
che SHP-1 possa svolgere un importante ruolo nella regolazione negativa di 
BCRABL e che la sua deregolazione possa concorrere alla progressione neoplastica 
della malattia. Per capire se le cause dei bassi livelli di SHP-1 nella linea cellulare 
resistente (KCL22r) fosse da ascrivere a meccanismi epigenetici, quali 
ipermetilazione del suo promotore, abbiamo approcciato un’analisi di methylation 
specific PCR (MSP) su una specifica sequenza del promotore dello stesso gene in 
entrambe le linee cellulari. Tale analisi ha mostrato l’ipermetilazione del promotore di 
SHP-1 solo nella linea resistente, mentre nella linea sensibile lo stesso promotore 
risulta del tutto non metilato (Fig.8). Tale analisi è stata  successivamente 
confermata mediante sequenziamento (Fig.9). La metilazione del DNA catalizzata da 
specifici enzimi ad attivita’ metiltransferasica, riguarda l’aggiunta di un gruppo 
metilico a carico di specifiche citosine inserite nel dincleotide CG, tali sequenze sono 
anche conosciute come isole CpG. Questo rappresenta un meccanismo alternativo 
di regolazione genica negativa utilizzato soprattutto per regolare geni coinvolti nello 
sviluppo. Vi sono molti casi in cui fenomeni di aberrante metilazione di alcuni geni 
sono correlati con fenomeni neoplastici. Alcuni studi hanno rivelato come la 
deregolazione dell’ espressione di SHP-1 in alcune patologie come Leucemie Acute, 
Mielomi e Linfomi sia da attribuirsi ad un’aberrante ipermetilazione del promotore 
[88,98]. Per capire il significato biologico dell’ipermetilazione del promotore di SHP-1 
nel sistema modello in esame, abbiamo trattato queste linee  con diverse 
concentrazioni  dell’inibitore di metiltransferasi 5-Azacitidine (5-AC). In seguito al 
trattamento, dal  punto di vista molecolare abbiamo osservato un aumento dei livelli 
sia del trascritto che della proteina di SHP-1 nella linea cellulare resistente (KCL22r). 
La riespressione di SHP-1 è stata anche accompagnata da una diminuzione dello 
stato di fosforilazione di ERK1/2 e STAT3 (Fig. 10). Nella linea sensibile (KCL22s) 
non sono state riscontrate variazioni sugli stessi pathway molecolari (Fig.10). 
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Parallelamente all’analisi molecolare, abbiamo vagliato anche l’effetto del trattamento 
con 5-AC sulla proliferazione ed il ciclo cellulare di queste cellule. Utilizzando la 
bromodeossiuridina, un analogo della timida capace di essere incorporato nel DNA di 
cellule in fase di sintesi, abbiamo analizzato la proliferazione delle KCL22 trattate. I 
risultati hanno mostrato una diminuzione della proliferazione cellulare sia nelle 
KCL22s che nelle KCL22r (Fig.11). Con lo ioduro di propidio, un intercalante del 
DNA, e successiva analisi citoflorimetrica, abbiamo riscontrato un accumulo di cellule 
in fase Go/G1 solo nella linea cellulare resistente (Fig.11). Quindi il trattamento con 
5-AC ha confermato che l’aberrante metilazione del promotore è alla base della 
down-espressione di SHP-1 nella linea resistente KCL22r e questo puo’ attivare una 
serie di vie di sopravvivenza alternative come MAPKs e JAK/STAs, indipendenti da 
Bcr/Abl, che permettono a queste cellule di sopravvivere anche in presenza di 
imatinib. Il passo successivo di questo lavoro è stato identificare i possibili interattori 
di SHP-1 e capire il significato biologico che questo comportasse. Esperimenti di co-
immunoprecipitazione  e western blot hanno mostrato l’interazione di SHP-1 con 
un'altra tirosin fosfatasi non recettoriale SHP-2 solo nella linea sensibile (KCL22s) 
mentre nella linea resistente non è stata riscontrata l’interazione (Fig.12). E’ da dire 
che queste due proteine mostrano un’elevata omologia di sequenza sono implicate 
nelle stesse vie di traduzione del segnale ma sembrano svolgere ruoli opposti. Infatti, 
mentre SHP-1 è generalmente considerato un regolatore negativo, SHP-2 è invece 
riconosciuto come modulatore positivo nelle stesse vie (Fig. 6) [96].  Real time PCR 
e western blot, hanno evidenziato come SHP-2 sia ugualmente espressa tra le due 
linee cellulari in esame (Fig7). L’interazione tra’ SHP-1 e 2 è stata gia’ riscontrata 
nella linea cellulare di adenocarcinoma colorettale Caco-2,  ma il significato di questa 
interazione resta ancora non chiaro [101]. Per capire se i bassi livelli di SHP-1 e la 
sua interazione con SHP-2 potessero essere coinvolti nei meccanismi molecolari di 
resistenza al trattamento con imatinib, abbiamo avviato ulteriori indagini funzionali. In 
particolare, avvalendoci della metodica dell’RNA interfirence,  abbiamo abbassato i 
livelli di SHP-1 nella linea sensibile (KCL22s), mimando quelle che erano le 
condizioni fisiologiche osservate nella linea resistente (KCL22r), mentre abbiamo 
spento l’espressione di SHP-2 nella linea resistente per capire l’effetto che questo 
potesse avere sulla risposta al trattamento con il farmaco.  
Da un punto di vista molecolare, il knock-down di SHP-1 nella linea sensibile 
(KCL22s), è stato accompagnato da un incremento dei livelli di fosforilazione di 
ERK1/2 (40%) e STAT3 (50%), mentre a seguito del knock-down di SHP-2 nella 
linea resistente (KCL22r), abbiamo osservato una diminuzione dello stato di 
fosforilazione di ERK1/2 (80%) e STAT3 (70%) (Fig.13). Questi dati sono molto simili 
a quelli osservati con cellule overesprimenti mutanti negativi per SHP-2 [102-103]. 
Allo stesso modo, le KCL22s interferite per SHP-1 e trattate con imatinib 1µM hanno 
mostrato una ridotta sensibilita’ al trattamento col farmaco. Il test di vitalita’ trypan 
blue ha evidenziato, dopo quattro giorni di trattamento,  una percentuale di cellule 
vitali (25%) piu’ alta nelle cellule interferite per SHP-1 rispetto alle stesse cellule non 
interferite prese come controllo e trattate allo stesso modo (Fig.14). Di contro, le 
KCL22r interferite per SHP-2 e trattate con imatinib 1µM hanno mostrato un aumento 
della sensibilita’ al trattamento col farmaco. Il test di vitalita’ trypan blue ha 
evidenziato, dopo quattro giorni di trattamento,  un decremento della percentuale di 
cellule vitali (50%) nelle cellule interferite per SHP-2 rispetto alle stesse cellule non 
interferite (Fig.14). E’ oggi ben accetto che SHP-2 abbia un ruolo critico nel 
sostenere l’attivazione dalla via di Ras/MAPK in risposta a diversi stimoli. Inoltre, la 
via di Ras/MAPK è ben descritta essere alla base di processi quali proliferazione e 
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differenziamento cellulare in risposta a fattori di sviluppo [96]. Per esempio, nelle 
cellule in cui è stato inattivato la funzione di SHP-2 è stato riscontrato una 
diminuzione dell’attivazione delle MAPK. Quindi questi ulteriori esperimenti funzionali 
hanno mostrato l’implicazione di SHP-1 e 2 nella risposta al trattamento con imatinib.  
Dunque, noi ipotizziamo che SHP-1 possa intervenire con la sua attivita’ fosfatasica 
a defosforilare specifici residui su SHP-2 mantenendola nella sua conformazione 
inattiva. A riguardo, è documentato in letteratura come la specifica defosforilazione 
dei residui tirosinici in posizione 542 e 580 posti al carbossiterminale di SHP-2 
possano concorrere a mantenere questa proteina nel suo stato inattivo [96]. Quindi, il 
giusto equilibrio tra SHP-1 e 2 potrebbe essere implicato nella risposta all’imatinib. In 
piu’, la deregolazione di questo sistema potrebbe sostenere alternative vie di 
sopravvivenza come Ras/MAPK e JAK/STATs che permettono a queste cellule di 
eludere l’azione del farmaco e continuare a proliferare. I dati raccolti nelle linee 
cellulari sono poi stati traslati nei pazienti. Mediante l’utilizzo di metodica RT-PCR 
abbiamo misurato i livelli del trascritto di SHP-1 nei leucociti, isolati dal midollo osseo 
mediante gradiente di Ficoll, di 60 pazienti affetti da LMC alla diagnosi. I pazienti 
sono stati suddivisi in tre sottogruppi in funzione della risposta che questi hanno 
ottenuto dopo 18 mesi di trattamento. I criteri di risposta utilizzati sono quelli descritti 
dall’Euroupean Leukemia Net (Tab.1) [54]. Abbiamo analizzato 35 pazienti definiti 
Optimal responder, 17 Suboptimal responder , ed 8 Failure responder. I livelli di 
SHP-1 sono stati normalizzati utilizzando il gene ABL ubiquitariamente espresso 
nella linea ematopoietica. I livelli di trascritto per SHP-1 sono risultati 
significativamente piu’ alti nei pazienti Optimal responder [rapporto SHP1/ABL 
5.8±1.77, (media±deviazione standard)] quando confrontati con i Suboptimal 
responder (3.8±1.3, *p=0.001) ed i Failure (3.2±1.04, *p=0.002) (Fig.15). Come 
controllo abbiamo misurato lo stesso trascritto in 21 pazienti affetti da sindrome 
mieloproliferativa cronica (CMDP), Ph negativi, e wild type per il gene JAK2, 
(6.0±2.2, *p=0.6). Con la stessa metodica, abbiamo misurato l’espressione di SHP-1 
nelle cellule primarie CD34+ isolate mediante cell sorting da 6 pazienti Optimal 
responder [1.7±0.25]  , e 6 Failure responder [0.9±0.15, *p=0.017] (Fig.16). Anche in 
questo caso i livelli di SHP-1 sono risultati piu’ bassi nei pazienti resistenti al 
trattamento. L’analisi sui pazienti ha quindi mostrato come pazienti resistenti al 
trattamento con imatinib presentino livelli piu’ bassi di SHP-1, statisticamente 
significativi, alla diagnosi. Nell’ultima parte di questo studio abbiamo cercato di capire 
se l’espressione di questa fosfatasi possa avere un ruolo predittivo ed essere 
utilizzato come marker di risposta al trattamento con imatinib nei pazienti affetti da 
LMC. Per questo scopo, abbiamo misurato sempre mediante RT-PCR l’espressione 
di SHP-1 nei leucociti, isolati dal sangue periferico,  di 48 pazienti con LMC alla 
diagnosi. Questi pazienti sono arruolati nel trial clinico TOPS (Tyrosine kinase 
inhibitor Optimization and Selectivity), uno studio randomizzato di fase III che  
confronta l’effetto della dose giornaliera di imatinib 800mg contro 400mg. Il fine di 
questo trial è confrontare l’effetto che questo produce su quella che viene indicata 
come risposta molecolare maggiore (MMR) [53], che sembra avere un ruolo 
predittivo nell’aspettativa di vita dei pazienti affetti da LMC e trattati con imatinib. I 
risultati sembrano indicare una significativa differenza nell’espressione di SHP-1 tra 
quei pazienti che ottengono o non ottengono la MMR dopo 12 mesi dall’inizio del 
trattamento [SHP1/ABL 7.4 ± 3.8 vs 6.0 ± 3.7, *p = 0.017] (Tab.2). Ulteriori analisi 
statistiche hanno anche mostrato come l’espressione di SHP-1 possa essere 
utilizzato come marker molecolare per la predizione della risposta molecolare 
maggiore (MMR) a 12 mesi nei pazienti con LMC e trattati con imatinib (Fig.17). 
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1 Introduction 
 
 
1.1 The BCR-ABL oncogene 
 
Chronic myelogenous leukaemia (CML) results from the neoplastic transformation of 
a haematopoietic stem cell (fig. 1). The hallmark genetic abnormality of CML is a 
t(9;22)(q34;q11) translocation, which was first discovered as an abnormal, small 
chromosome, named the 'Philadelphia chromosome' (Ph+). The Ph+ chromosome 
was originally described as a chromosomal abnormality in 1960 by Nowell and 
Hungerford [1]. In 1973, Rowley reported that this abnormal chromosome, found in 
most patients with chronic myeloid leukemia (CML), has an apparent loss of the long 
arm of chromosome number 22 and is the result of reciprocal translocation involving 
the long arms of chromosomes 9 and 22, t(9;22) [2]. The molecular genetics of the 
Ph+ chromosome showed the ABL gene to be on the segment of chromosome 9 
that is translocated to chromosome 22 [3]. Breakpoints in chromosome 22 were 
found to occur over a very short stretch of DNA (5–6 kb), termed the breakpoint 
cluster region (BCR) gene. The native c-ABL tyrosine kinase is located partially in 
the nucleus and has tightly regulated kinase activity. The BCR–ABL fusion results in 
the production of a constitutively active cytoplasmic tyrosine kinase that does not 
block differentiation, but enhances proliferation and viability of myeloid lineage cells. 
BCR–ABL is likely sufficient to cause CML, but over time other genetic events occur 
and the disease progresses to an acute leukemia. CML is typically characterized by 
phases of variable duration, starting with an initial chronic phase (CP), followed by 
progression to accelerated phase (AP) and finally resulting in blast crisis (BC) [4]. 
The initial chronic phase of this biphasic disease is characterized by a massive 
expansion of the granulocytic cell lineage, even though most, if not all, 
haematopoietic lineages can be produced from the CML stem cell. The median 
duration of the chronic phase is 3–4 years. Acquisition of additional genetic and/or 
epigenetic abnormalities causes the progression of CML from chronic phase to blast 
phase. This phase is characterized by a block of cell differentiation that results in the 
presence of 30% or more myeloid or lymphoid blast cells in peripheral blood or bone 
marrow, or the presence of extramedullary infiltrates of blast cells. 
 
 
1.2 Structure of the BCR-ABL fusion genes and their transcripts  
Breakpoints in ABL  
Breakpoints within the ABL gene can occur anywhere within a 5′ segment that 
extends for over 300 kilobases (kb) [5]. Typically, breakpoints form within intronic 
sequences, most frequently between the two alternative first exons of ABL. Thus, 
BCR-ABL fusion genes may contain both exons 1b and 1a, exon 1a alone, or neither 
of the alternative first exons. BCR-ABL mRNA lacks exon 1, regardless of the 
structure of the fusion gene, with the transcript consisting of BCR exons fused 
directly to ABL exon a2 (Fig.2). 
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Fig.1 Chronic myelogenous leukaemia (CML) is a biphasic disease, initiated by 
expression of the BCR–ABL fusion gene product in self-renewing, haematopoietic 
stem cells (HSCs). HSCs can differentiate into common myeloid progenitors 
(CMPs), which then differentiate into granulocyte/macrophage progenitors (GMPs; 
progenitors of granulocytes (G) and macrophages (M)) and 
megakaryocyte/erythrocyte progenitors (MEPs; progenitors of red blood cells 
(RBCs) and megakaryocytes (MEGs), which produce platelets). HSCs can also 
differentiate into common lymphoid progenitors (CLPs), which are the progenitors of 
lymphocytes such as T cells and B cells. The initial chronic phase of CML (CML-CP) 
is characterized by a massive expansion of the granulocytic-cell series. Acquisition 
of additional genetic mutations beyond expression of BCR–ABL causes the 
progression of CML from chronic phase to blast phase (CML-BP). 
 
1.2.1 Breakpoints in BCR  
The breakpoints within the BCR gene on chromosome 22 are found within three 
defined regions [5]. In 95% of patients with CML and approximately one third of 
patients with ALL, the BCR gene is truncated within a 5.8-kb region known as the 
major breakpoint cluster region (M-bcr) (Fig.2). This region contains five exons, 
originally named b1 to b5, but now referred to as e12 to e16, according to their true 
positions in the gene [6]. Most breakpoints form within introns immediately 
downstream of exon 13 (b2) or exon 14 (b3). Because processing of BCR-ABL 
mRNA results in the joining of BCR exons to ABL exon a2, hybrid transcripts are 
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produced that have an e13a2 (b2a2) or an e14a2 (b3a2) junction. In both cases, the 
mRNA consists of an 8.5-kb sequence that encodes a 210-kd fusion protein, p210Bcr-
Abl
 (Fig. 2). In two-thirds of patients with Ph-positive ALL and in rare cases of CML 
and acute myelogenous leukemia, the breakpoint in BCR occurs in a region 
upstream of the major breakpoint cluster region known as the minor breakpoint 
cluster region (m-bcr) (Fig.2). This region consists of the 54.4-kb intron between the 
two alternative second exons of the BCR gene, e2′ and e2. BCR-ABL fusion genes 
that have breakpoints within the minor breakpoint cluster region contain both BCR 
alternative first exons (e1 and e1′) together with the alternative second exon (e2′). 
Chimeric RNA derived from these fusion genes evidently is subject to splicing 
because the mature transcripts lack exons e1′ and e2′. The hybrid mRNA consists of 
sequences that are approximately 7 kb in length in which exon e1 from BCR is 
joined to exon a2 of ABL. The translated product is a 190-kd fusion protein, p190Bcr-
Abl
 (also referred to as p185Bcr-Abl) [7]. Interestingly, transcripts with an e1a2 junction 
are detectable at very low levels in patients with a major breakpoint cluster region 
rearrangement. Initially thought to be indicative of disease progression [8], these 
transcripts subsequently were detected irrespective of the phase of disease [9-10]. 
Their low level of expression in comparison to the predominant p210Bcr-Abl message 
suggests that the e1a2 transcripts most likely are the result of alternative splicing of 
e13a2 or e14a2 transcripts [10-11]. The third defined breakpoint cluster region within 
the BCR gene was named “micro” breakpoint cluster region (µ-bcr),(Fig.2) [12]. In 
this case, the breaks occur within a 3′ segment of the BCR gene between exons e19 
and e20 (known as c3 and c4 in the original nomenclature). Transcription of the 
hybrid gene yields an e19a2 BCR-ABL fusion transcript that encodes a 230-kd 
protein, p230Bcr-Abl. 
 
Fig. 2 The t(9;22) translocation and its products with breakpoint locations at the BCR 
and ABL loci. 
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1.3 Molecular pathophysiology 
Cells expressing the chimeric BCR–ABL oncoprotein show signs typical of malignant 
transformation, including excessive cell growth of immature myeloid cells with lack of 
differentiation and inhibition of apoptosis [13]. The mechanisms through which BCR–
ABL contributes to malignant transformation have been extensively studied by using 
BCR–ABL expressing murine or human cell models. Many of the activated signaling 
pathways are normally regulated by hematopoietic growth factors, such as c-kit 
ligand, thrombopoietin, interleukin-3, or granulocyte/macrophage-colony stimulating 
factor. Not surprisingly, it has been demonstrated that BCR–ABL activates a variety 
of signaling pathways and downstream targets like RAS, STATs, 
phosphatidylinositol-3′-kinase, production of reactive oxygen species (ROS) and 
others that can also be activated by hematopoietic growth factors. A major difference 
between activated growth factor receptors in normal signaling and BCR–ABL is the 
dysregulated activation of signaling pathways by BCR–ABL, inducing abnormal 
proliferation and neoplastic expansion. In addition, the BCR–ABL oncoprotein 
decreases apoptotic reaction to mutagenic stimuli, which results in a survival 
advantage to the neoplastic clones [14]. In many model systems, BCR–ABL 
completely abrogates growth factor dependence, and has been associated with 
reduced requirement for growth factors in primary hematopoietic cells. It is clear, 
however, that there are other activities of BCR–ABL that remain poorly understood, 
in particular, the propensity for CML to evolve into blast crisis. 
 
Fig.3 Leukaemogenic signallilg of BCR/ABL. The BCR–ABL proteins can form 
dimers or tetramers through their CC domains, and trans-autophosphorylate 
(indicated by up and down arrows between protein structures). Phosphorylation at 
the Y177 residue generates a high-affinity binding site for growth factor receptor-
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bound protein 2 (GRB2). GRB2 binds to BCR–ABL through its SH2 domain and 
binds to SOS and GRB2-associated binding protein 2 (GAB2) through its SH3 
domains. SOS in turn activates RAS. Following phosphorylation (P) by BCR–ABL, 
GAB2 recruits phosphatidylinositol 3-kinase (PI3K) and SHP2 proteins. The SH2 
domain of ABL can bind SHC, which, following phosphorylation can also recruit 
GRB2. The ABL SH3 domain and the SH3 binding sites in the carboxy-terminal 
region can bind several proteins that involve regulations of cell adhesion/migration. 
Interferon consensus sequence binding protein (ICSBP), also known as interferon 
regulatory factor 8, negatively regulates proliferation and survival of myeloid cells by 
inducing differentiation of monocytic cells. JUNB inhibits cell proliferation and 
survival, partly by antagonizing the RAS downstream target JUN. SIPA1 (signal-
induced proliferation-associated gene-1) is a RAP1 GAP that keeps RAP1 inactive. 
BCR–ABL can promote cell proliferation and survival partly by activating the RAS, 
SHP2 and PI3K–AKT signalling pathways. It can also downregulate transcription of 
ICSBP and JUNB, and might also inhibit SIPA1. Red arrows indicate direct 
interactions and/or activations. Black arrows indicate negative regulations. Broken 
arrows indicate multiple steps. ABD, actin-binding domain; CC, coiled-coil; DBD, 
DNA-binding domain; DH, Dbl/CDC24 guanine-nuleotide exchange factor homology; 
NES, nuclear exporting signal; NLS, nuclear localization signal; PP, proline-rich SH3 
binding site; S/T-K, serine/threonine kinase; Y-K, tyrosine kinase. 
 
1.4 Pathway downstream of BCR-ABL 
Many signalling proteins have been shown to interact with BCR–ABL through 
various functional domains/motifs (for example, GRB2, CRKL, CRK, SHC, 3BP2, 
ABL-interacting protein 1 and 2, and CRK-associated substrate (CAS)), and/or to 
become phosphorylated in BCR–ABL-expressing cells (for example, CRKL, CRK, 
SHC, docking protein 1, GAB2, CBL, CAS, signal transducer and activator of 
transcription 5 (STAT5), the p85 subunit of PI3K, phospholipase C , synaptophysin, 
VAV1, RAS GTPase-activating protein, focal adhesion kinase, FES, paxillin and talin 
[15-16]. These proteins in turn activate a range of signalling pathways that activate 
proteins such as RAS, PI3K, AKT, JNK, SRC family kinases, protein and lipid 
phosphatases, and their respective downstream targets, as well as transcription 
factors such as the STATs, nuclear factor-kB and MYC [16]. BCR–ABL also induces 
expression of cytokines such as interleukin-3 (IL-3), granulocyte colony-stimulating 
factor and granulocyte–macrophage colony-stimulating factor (GM-CSF) [17]. Most 
of these findings were observed from experiments in in vitro systems, or from 
studies of the properties of cells derived from leukaemia patients with particular 
stages of disease. The importance of these signalling proteins and pathways in 
leukaemogenesis and their viability as therapeutic targets needs to be validated by 
in vivo model systems. Mouse models can be used to determine the involvement of 
these signalling pathways in CML pathogenesis and progression. The 
leukaemogenic role of various factors that are activated by BCR–ABL expression 
has been effectively examined using knockout mice. Expression of BCR–ABL in 
bone-marrow cells, through retroviral transduction, still induced CML-like MPD in 
Stat5a-/-Stat5b-/-, Cbl-/- and Il-3-/-GM-CSF-/- mice [18-20], so these proteins are not 
required for BCR–ABL-mediated leukaemogenesis. BCR–ABL expression also 
induced CML-like MPD in mice that lacked the SRC family kinases LYN, 
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haematopoietic cell kinase and FGR, although it failed to induce B-ALL in these mice 
[21]. Interestingly, downregulating LYN expression by small interfering RNA induces 
apoptosis of human blast-phase CML cells, particularly the lymphoid blast cells [22].  
Together these results indicate that LYN is important in the development of blast-
phase CML particularly for lymphoid blast crisis  but not for chronic-phase CML. 
BCR–ABL also recruits the scaffold adapter GAB2 through GRB2. The major GRB2-
binding site at Y177 of BCR–ABL was shown to regulate the tyrosine 
phosphorylation of GAB2 [23], indicating that GAB2 is a substrate of BCR–ABL. 
Consistent with the importance of Y177 function in BCR–ABL-mediated 
leukaemogenesis, BCR–ABL was unable to confer cytokine-independent growth (a 
characteristic of leukaemia cells) in primary myeloid cells isolated from Gab2-/- mice 
in vitro [23]. So, the inability of the Y177F mutant of BCR–ABL to induce leukaemia 
might be partially due to a failure to transmit appropriate signals through GAB2. 
GAB2 contains binding sites for the SH2 domains of the p85 subunit of PI3K and for 
SHP2 [23]. The PI3K pathway has been implicated in a wide range of human 
cancers [24]. Mutations of the SHP2 gene (also known as PTPN11) have also been 
found in approximately 50% of individuals with Noonan syndrome, a common human 
autosomal-dominant birth defect characterized by short stature, facial abnormalities, 
heart defects and possibly increased risk of leukaemia [25]. The PI3K and SHP2 
signalling pathways could be required for BCR–ABL leukaemogenesis and therefore 
be effective therapeutic targets for CML. SHP2 is required for normal activation of 
the RAS–ERK (extracellular signal-regulated kinase) pathway that most receptor 
tyrosine kinases and cytokine receptors signal through  [26]. The mechanism of the 
activation of RAS–ERK pathway by SHP2 is not completely known. In addition to 
SHP2, RAS can be activated directly by BCR–ABL through the GRB2–SOS complex 
[27,28]. (Fig. 3). Mutations that result in constitutive activation of RAS are associated 
with approximately 30% of all human cancers, including 20–30% of cases of AML, 
MPDs and myelodysplastic syndrome [29]. . Recently, it was shown that expression 
of an oncogenic KRAS using a conditional knock-in line of mice efficiently induced 
an MPD that resembled human chronic myelomonocytic leukaemia (CMML) [30]. 
We found that expression of oncogenic NRAS in mice, through BMT, efficiently 
induced CMML- or AML-like disease in mice (R. Subrahmanyam, C. Parikh and 
R.R., unpublished observations). We also found that co-expression of oncogenic 
NRAS and the Y177F mutant of BCR–ABL could rapidly and efficiently induce CML-
like myeloproliferative disorder (R. Subrahmanyam and R.R., unpublished 
observations). So RAS seems to be a crucial downstream target of BCR–ABL, yet 
other signalling pathways activated by BCR–ABL restrict BCR–ABL-mediated 
leukaemogenesis in the granulocytic lineage. Gene-knockout studies also revealed 
several key negative regulators of myelopoiesis. Mice with disruptions of the gene 
encoding interferon consensus sequence binding protein (ICSBP), also known as 
interferon regulatory factor 8, developed a CML-CP-like disease at 10–16 weeks of 
age, in addition to defects of viral and intracellular parasite immunity [31]. One-third 
of the mice also underwent blast crisis by 50 weeks of age. Consistent with the 
myeloid phenotype of the Icsbp-null mice, it was shown that ICSBP controls the 
development of myeloid cells by stimulating macrophage differentiation while 
inhibiting granulocyte differentiation, in both cases inhibiting cell growth [32] (Fig. 3). 
Expression of the ICSBP protein is significantly decreased in mice with BCR–ABL-
induced CML-like disease, and forced expression of ICSBP inhibited the BCR–ABL-
induced colony formation of bone-marrow cells in vitro and BCR–ABL-induced CML-
like disease in vivo [33]. Downregulation of ICSBP transcripts was also found in 
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patients with CML, and this reduction could be reversed by treatment with interferon  
[34]. These data indicate that ICSBP is a tumour suppressor and that 
downregulation of ICSBP is important for the pathogenesis of CML. Consistent with 
the importance of the RAS signalling in promoting growth of myeloid cells, JUNB, an 
antagonist of the RAS downstream target JUN and negative regulator of cell 
proliferation and survival, was shown to act as a tumour suppressor in myeloid cells. 
Junb-null mice have severe vascular defects in the placenta, leading to early 
embryonic lethality [35]. However, inactivation of JUNB specifically in 
haematopoietic cells led to the development of a CML-like disease in mice, 
beginning at 4 months of age [36]. About 16% of mice further developed a syndrome 
that resembled blast crisis. More recent studies showed that JUNB inactivation in the 
long-term self-renewing haematopoietic stem cells of mice, but not in committed 
myeloid progenitor cells, could induce a CML-like myeloproliferative disorder. 
Furthermore, only JUNB-deficient long-term self-renewing haematopoietic stem cells 
from the diseased mice could induce CML-like disease in recipient mice after 
transplantation [36].  These results support the hypothesis that CML originates from 
haematopoietic stem cells. Downregulation of JUNB has also been observed in CML 
cells isolated from patients [37].  These results indicate that inactivation of JUNB 
could be important for CML development. There is further support for the importance 
of RAS downstream signalling pathways in myeloid proliferation and survival. 
Targeted inactivation of SIPA1 (signal-induced proliferation-associated gene-1) a 
principal RAP1 GTPase-activating protein in haematopoietic progenitors led to a 
spectrum of myeloid disorders that resembled chronic-phase CML, blast-phase CML 
and myelodysplastic syndrome by 1 year after birth in mice [38]. In pre-leukaemic 
SIPA1-deficient mice, there is a selective expansion of pluripotential haematopoietic 
progenitors. RAP1 is a close member of RAS-family GTPases and, like RAS, can 
activate the mitogen-activated kinase/ERK kinase (MEK)–ERK signalling pathway 
through activation of BRAF [39]. It is not clear whether expression or activity of 
SIPA1 is altered in CML cells, but it was shown that expression of BCR–ABL in a 
growth-factor-dependent haematopoietic cell line activated RAP1 and BRAF [40]. 
These results indicate that in addition to the well-established RAS signalling 
pathway, BCR–ABL might activate MEK–ERK signalling through a pathway involving 
RAP1 and BRAF (Fig. 3). In mice, disruption of the genes encoding SH2-containing 
inositol-5-phosphatase (SHIP) also leads to a massive expansion of myeloid cells in 
the lung, bone marrow and spleen [41]. About half of these mice die at 14 weeks of 
age. Expression of BCR–ABL in growth-factor-dependent haematopoietic cells 
downregulates SHIP, so inactivation of SHIP somehow contributes to BCR–ABL 
leukaemogenesis [42]. However, in CML cells isolated from patients, SHIP 
expression seems to be differently altered in the early and late stages of 
differentiation [43]. In addition, SHIP-null primitive haematopoietic cells showed 
modestly reduced growth-factor independence. These results indicate that SHIP 
could have both positive and negative roles in haematopoiesis, depending on the 
cell context.                                                                                                                                                                                                                                                                                                                    
 
1.5 CML therapies 
Allogeneic stem-cell transplantation is the only known curative therapy for CML. 
However, most patients are not eligible for this therapy, because of advanced age 
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(making them unable to tolerate the serious side effects of the treatment) or lack of a 
suitable stem-cell donor [44]. The discovery that BCR–ABL is required for the 
pathogenesis of CML, and that the tyrosine-kinase activity of ABL is essential for 
BCR–ABL-mediated transformation, made the ABL kinase an attractive target for 
therapeutic intervention [45]. Imatinib mesylate (Glivec, previously known as STI571) 
a potent inhibitor of the tyrosine kinases ABL, ARG, platelet-derived growth factor 
receptor and KIT has been shown to selectively induce apoptosis of BCR–ABL+ cells 
[46,47], and is remarkably successful in treating patients with CML [48] (Fig. 4). In 
newly diagnosed patients with CML in chronic phase, imatinib induces complete 
cytogenetic response in more than 80% patients. Patients with more advanced 
phases of CML also respond to imatinib, but this occurs much less frequently and 
treatment is less durable [48].Today Imatinib is the front line terapy in the CML 
treatment. However, there are two major obstacles to imatinib-based therapies for 
patients with CML. One is the persistence of BCR–ABL-positive cells this is known 
as 'residual disease', and is detected by a sensitive nested reverse-transcriptase 
PCR assay [49,50]. Suppression of the disease therefore relies on continuous 
imatinib therapy. The other major problem is relapse of the disease due to the 
emergence of resistance to imatinib [51]. Several mechanisms of resistance have 
been described, the most frequent of which are the appearance of point mutations in 
the BCR–ABL gene that impair the drug binding [51,52].  
 
 
 
Fig.4. Imatinib Action. Imatinib works by binding to the ATP binding site of Bcr/Abl 
and inhibiting the enzyme activity of the protein competitively. Inibition of Bcr/Abl 
activity blocks deregulated signaling as alterated cellular adhesion, abnormal 
proliferation and apoptosis inhibition. 
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1.6 Clinical resistance to imatinib 
The efficacy of imatinib in CML is remarkable, but the development of resistance and 
the persistence of minimal residual disease have dampened the initial enthusiasm 
for this much heralded ‘magic bullet’. Resistance can be defined on the basis of its 
time of onset. Primary resistance is a failure to achieve a significant haematological 
or cytogenetic response, whereas secondary or acquired resistance is the 
progressive reappearance of the leukaemic clone after an initial response to the 
drug. Resistance is also defined on the basis of clinical and laboratory criteria used 
for detection of leukaemia, which includes haematological, cytogenetic and 
molecular resistance. Haematological resistance is a lack of normalisation of 
peripheral blood counts and spleen size; cytogenetic resistance is a failure to 
achieve a major cytogenetic response, i.e. less than 35% Philadelphia (Ph) 
chromosome positivity; and molecular resistance represents the failure to achieve or 
the loss of complete or major molecular response (MMR). MMR can be defined as a 
3 or more log-reduction of BCR-ABL/control gene ratio from a laboratory 
standardised baseline or an international scale converted BCR-ABL/control gene 
ratio of <0.1% [53]. Recently, the European Leukaemia Net refined response criteria 
allowing resistance to be categorised into 2 groups, ‘suboptimal response’ and 
‘failure to respond’ (Table 1). Continuing imatinib treatment is unlikely to be 
beneficial in those with failure to respond, while the suboptimal responders may still 
have a benefit in continuing, although with a less favourable long term outcome [54]. 
 
Duration of treatment 
(months) Failure Suboptimal response 
3 • No HR • Less than CHR 
6 • Less than CHR • Less than PCyR 
 • No cytogenetic response  
12 • Less than PCyR • Less than CCyR 
18 • Less than CCyR • Less than MMR 
Any time • Loss of CHR • Ph-positive clonal evolution 
 • Loss of CCyR  
 • Disease progression • Loss of MMR 
 
• Mutations with high level 
imatinib-insensitivity 
• Mutations with low level 
imatinib-insensitivity 
 
Table 1. Definition of failure and suboptimal response for previously untreated CML-
early chronic phase patients treated with imatinib 400 mg daily. Abbreviations: HR, 
haematological response; CHR, complete haematological response with recovery of 
peripheral blood counts; CCyR, complete cytogenetic response (0% Ph chromosome 
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positive marrow metaphases); PCyR, partial cytogenetic response (1–35% Ph 
chromosome positive marrow metaphases). 
 
1.6.1 Molecular basis of resistance 
Ever since the first reports of resistance were described in 2000, the mechanisms of 
resistance to imatinib have been extensively studied and three major mechanisms of 
resistance have been identified. The two most common affect the BCR-ABL gene 
itself, namely mutations in its tyrosine kinase domain and overexpression of the Bcr-
Abl protein due to amplification of the BCR-ABL gene [55-57]. The third mechanism 
is less well characterised and understood, and is represented by phenomena which 
lead to resistance independent of Bcr-Abl. These include upregulation of the drug 
efflux pumps [55], [58-60], downregulation of drug influx transporters [61-62], binding 
of the α1-acid glycoprotein (AGP) [63], overexpression of Lyn, a Src kinase [64], and 
other Bcr-Abl-independent mechanisms [65]. 
 
1.6.2 Mutations in the Abl kinase domain 
The emergence and selection of clones exhibiting point mutations in the Abl kinase 
domain is the most frequently identified mechanism of resistance in patients treated 
with imatinib and is more common in acquired than in primary resistance [66]. These 
mutations are not induced by imatinib, but rather, just like antibiotic resistance in 
bacteria, arise through a process whereby the drug itself selects for rare pre-existing 
mutant clones, which gradually outgrow drug-sensitive cells [67]. Mutations can be 
categorised into 4 groups: (i) those which directly impair imatinib binding; (ii) those 
within the ATP binding site; (iii) those within the activation loop, preventing the 
kinase from achieving the conformation required for imatinib binding; and (iv) those 
within the catalytic domain (Fig. 5). The substitution of the amino acid threonine with 
isoleucine at position 315 of the Abl protein was the first mutation to be detected in 
resistant patients [68]. Based on the crystal structure of the catalytic domain of Abl 
complexed to a variant of imatinib [69], this substitution was predicted to reduce the 
affinity for the drug in two ways. Firstly, the oxygen atom provided by the side chain 
of threonine 315 is not present, and this prevents the formation of a hydrogen bond 
with the secondary amino group of imatinib. Secondly, isoleucine contains an extra 
hydrocarbon group on its side chain and this sterically inhibits the binding of the 
inhibitor [68]. Another amino acid that makes contact with imatinib is phenylalanine 
317, and its mutation to leucine also leads to resistance. Mutations can also cluster 
within the ATP-binding loop (phosphate or P-loop). This domain is a highly 
conserved glycine-rich sequence that spans amino acids 248–256 and interacts with 
imatinib through hydrogen and van der Waals bonds [66]. These mutations modify 
the flexibility of the P-loop and destabilise the conformation required for imatinib 
binding [70]. Apart from imatinib insensitivity, a feature of clinical relevance is that 
imatinib-treated patients who harbour P-loop mutations have been suggested to 
have a worse prognosis than those with non-P-loop mutations [56]. However, this 
has not yet been confirmed in larger series. The activation loop of the Abl kinase 
begins at amino acid 381 with a highly conserved motif of 3 amino acid residues 
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(aspartate–phenylalanine–glycine). This region of the kinase can adopt a closed 
(inactive) or an open (active) conformation. Imatinib forces Abl into the inactive 
conformation and is incapable of binding to the active configuration [71]. Mutations in 
the activation loop may disturb the energetic balance required to stabilise the closed 
conformation of the loop and thus favour the open, active conformation [70]. Finally, 
some amino acid substitutions cluster in the catalytic domain, a region that has a 
close topologic relation to the base of the activation loop. Mutations in this region 
can also influence the binding of imatinib [70]. At least 73 different point mutations 
leading to substitution of 50 amino acids in the Abl kinase domain have been 
isolated from CML patients resistant to imatinib so far, and this number is likely to 
increase with more sensitive methods of detection (Fig.5). 
 
 
 
 
 
Fig. 5 Map of Bcr-Abl kinase domain mutations associated with clinical resistance to 
imatinib. Abbreviations: P, P-loop; B, imatinib binding site; C, catalytic domain; A, 
activation loop. Amino-acid substitutions in green indicate mutations detected in 2–
10% and in red in >10% of patients with mutations.  
 
The detection of a Ph-positive clone harbouring an Abl kinase domain mutation is 
associated with resistance to imatinib and may be associated with progression to a 
more advanced phase disease [56] and [57]. Using highly sensitive assays, 
mutations have also been detected in patients in complete cytogenetic response, 
and in imatinib-naïve advanced phase but not chronic phase patients [72]. However, 
detection of mutations in these patients did not always result in progressive disease 
while on imatinib. It is likely that mutant clones in the presence of low leukaemic 
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burden or low levels of mutant clones do not have a similar clinical impact as clones 
which are detected when disease burden is rising or high [72]. Furthermore, the 
probability of detecting a clone is low when BCR-ABL transcript levels are stable or 
declining [73]. 
 
1.6.3 Bcr-Abl overexpression 
Overexpression of the Bcr-Abl protein due to amplification of the BCR-ABL gene 
was first observed in vitro when resistant CML cell lines were generated by exposure 
to gradually increasing doses of imatinib [55], [74]. This phenomenon has been 
reported in a relatively small proportion of patients, with an overall percentage of 
18% [68], [66], but this may be an underestimate if its detection is only based on the 
cytogenetic findings of Ph chromosome duplication. In one study, 3 out of 11 CML 
patients in blast crisis who relapsed after initially responding to imatinib were shown 
to have multiple copies of the BCR-ABL gene by fluorescence in situ hybridisation 
(FISH) [68]. In another study, 7 out of 55 patients showed a more than 10-fold 
increase in BCR-ABL transcript levels and 2 out of the 32 patients evaluated were 
found to have genomic amplification of BCR-ABL by FISH [66]. In the latter 2 
patients, resistance was primary and not acquired. Overexpression of Bcr-Abl leads 
to resistance by increasing the amount of target protein needed to be inhibited by 
the therapeutic dose of the drug. It is also possible that a transient overexpression of 
Bcr-Abl may be an early phenomenon in the establishment of imatinib resistance, 
preceding the emergence of a dominant clone with a mutant kinase domain, as 
suggested by kinetic studies in cell lines [74]. 
 
1.6.4 Drug efflux and influx transporters 
Multidrug resistance (MDR) due to cross-resistance of mammalian cells to a number 
of anticancer agents following exposure to one such drug is a well described 
mechanism of resistance in cancer therapy. This is mediated by an increased 
expression at the cell surface of the MDR1 gene product, Pgp, an energy dependent 
efflux pump, which reduces intracellular drug concentrations and leads to ineffective 
levels of the drug reaching its target [75]. Imatinib and other tyrosine kinase 
inhibitors are substrates of Pgp, and the intracellular levels of imatinib were shown to 
be significantly lower in Pgp-expressing cells [61], [76-77]. An imatinib-resistant CML 
cell line generated by gradual exposure to increasing doses of the drug was shown 
to exhibit Pgp overexpression, and MDR1 overexpression in CML cell lines also 
confers resistance to imatinib [55] and [58]. Pgp overexpression has not been 
reported in patients who are resistant to imatinib. However, the addition of a Pgp 
pump inhibitor, PSC833, to cultures of imatinib-treated cells from drug-resistant CML 
patients produced a significant decrease in colony formation, thus suggesting that 
MDR1 overexpression may play a role in clinical imatinib resistance [58]. Recently, 
two other drug transporters, breast cancer resistance protein (BCRP)/ABCG2 and 
human organic cation transporter 1 (hOCT1), have been implicated as possible 
mechanisms for promoting imatinib resistance. Imatinib has been variably reported 
to be a substrate and/or an inhibitor for the BCRP/ABCG2 drug efflux pump which is 
overexpressed in many human tumours and also found to be functionally expressed 
in CML stem cells [59-60]. The drug transporter, hOCT1 mediates the active 
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transport of imatinib into cells, and inhibition of hOCT1 decreases the intracellular 
concentration of imatinib, which may predict for a less favourable molecular 
response [61] and [62]. The hOCT1 gene was also found to be expressed in 
significantly higher levels in patients who achieved a complete cytogenetic response 
to imatinib than in those who were more than 65% Ph chromosome positive after 10 
months of treatment. This would suggest that patients with low baseline expression 
of hOCT1 may not achieve a complete cytogenetic response because of insufficient 
intracellular levels of imatinib. 
 
1.6.5 Bcr-Abl-independent mechanisms 
The Src family kinases, Lyn and Hck, are activated in BCR-ABL-expressing cell 
lines. Lyn is overexpressed and activated in an imatinib-resistant CML cell line 
generated by incubation of the parental line in increasing concentrations of imatinib 
and in samples from CML patients who were resistant to imatinib [64]. Lyn 
suppression by a Src kinase inhibitor resulted in reduced proliferation and survival of 
the imatinib-resistant but not the sensitive cell line [64]. Microarray analysis have 
shown that transcripts from genes with anti-apoptotic or malignant transformation 
properties and with involvement in signal transduction/transcriptional regulation are 
overexpressed in CML cells innately resistant to imatinib. This would suggest that 
pathways downstream of Bcr-Abl and independent of its kinase activity may be 
important factors which confer resistance to imatinib [65]. 
 
1.7 SHP-1 and SHP-2 phosphatases 
Although rare in chronic phase myeloid leukemia (CML), primary or acquired 
resistance to the treatment with tyrosine kinase inhibitors (TKI) Imatinib may be 
observed in the advanced phases of disease. Bcr/Abl related mechanisms of 
resistance, i.e. K. D. mutations have been well described, while the other 
mechanisms of resistance are poorly understood. Many studies have been focused 
on the role of other tyrosine kinases in BCR/ABL transformed cells as modulation of 
leukemic phenotype and as determinants of resistance to the treatment with 
Imatinib.  Howewar, very few data are available on the possible role of tyrosine 
phosphatases in Ph+ cells and in patients, who lack or loose response to the 
Imatinib treatment. In this study, we investigate the role of two SH2-containing, non-
receptor protein tyrosine phosphatases (Shp1 and Shp2) in the resistance to Imatinib 
(Ima). SHP-1 is generally considered as a negative signal transducer and SHP-2 as 
a positive one. However, the precise role of each enzyme in shared signaling 
pathways is not well defined. SHP-1 and SHP-2 are Src homology 2 (SH2) domain-
containing tyrosine phosphatases. High expression of SHP-1 and SHP-2 in the 
hematopoietic system suggests that these two tyrosine phosphatases play important 
roles in hematopoietic cell functions. SHP-1 is highly expressed in hematopoietic 
cells and, at a lower level, in various nonhematopoietic cells, whereas SHP-2 is 
ubiquitously expressed [78]. Both SHP-1 and SHP-2 have important physiological 
roles and may be implicated in neoplastic transformation of hematopoietic cells. 
SHP-1 generally exerts a negative effect upon the hematopoietic differentiation of 
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embryonic stem cells (ESC) and may act at different stages of embryonic stem cell 
differentiation [79]. In mice, mutation of the SHP-1 gene is responsible for the 
motheaten and viable motheaten phenotypes [80-81]. In humans, reduction of SHP-
1 gene expression is observed in natural killer cell lymphomas as well as other types 
of lymphomas/leukemias [82-83]. Methylation of the SHP-1 promoter causes loss of 
SHP-1 expression in malignant T-lymphoma cells [84]. Interestingly, decreased 
expression level of SHP-1 is associated with progression of Chronic myeloid 
leukaemia (CML) [85]. Moreover, Shp1 was shown to be physically associated with 
Bcr-Abl with evidence supporting their functional interaction [86-87]. More recent 
studies showed that Shp1 protein and mRNA are absent in the CML blast cell line 
K562 [87-88], whereas differentiation of K562 cells was associated with regulation of 
Shp1 expression [87]. On the other hand, forced expression of Shp1 blocks 
transformation by Bcr-Abl [89]. These observations indicate that Shp1 plays a 
significant role in the negative regulation of Bcr-Abl and that lack of Shp1 is 
important for CML transformation. On the other hand, SHP-2 has been shown to be 
required for development of hemangioblast and progenitor hematopoietic cell 
development [90]. Down modulation of SHP-2 expression, through SHP-2 siRNA 
transfection, significantly decreases the formation of hematopoietic progenitor 
formation and also blocks fibroblast growth factor induced hemangioblast formation 
[91]. Development of embryonic cells with a homozygous SHP-2 mutation leads to 
the suppression of hematopoietic cell differentiation. Activation mutation of SHP-2 
causes Noonan syndrome [92], an autosomal dominant disorder characterized by 
dysmorphic facial features, proportionate short stature, and heart disease (most 
commonly pulmonic stenosis and hypertrophic cardiomyopathy). This gain-of-
function mutation of SHP-2 is also associated with sporadic juvenile myelomonocytic 
leukemia, myelodysplasic syndrome, acute lymphoblastic leukemia, and acute 
myelogenous leukemia [93-94]. Furthermore, SHP-2 is an intracellular target of 
Helicobacter pylori CagA protein [95] that is associated with severe gastritis and 
gastric cancer. SHP-1 and SHP-2 share over 55% sequence identity and are 
regulated by similar mechanisms. However, their biological functions seems to be 
quite different (Fig.6) [96]. Since, motheaten and viable motheaten mice, which have 
germiline mutation of the SHP-1 gene, develop a severe auto-immune and 
immunodeficiency syndrome characterized by increased numbers of many 
hematopoietic cells [80-81]; SHP-1 is generally considered a negative regulator of 
cell proliferation. At molecular level SHP-1 dephosphorylates receptors of growth 
factors, cytokines, and antigens, and tyrosine-phosphorylated proteins associated 
with these receptors, and therefore, it is often defined as a negative regulator of 
signal transduction and of cytokine signals acting on hematopoietic cells. On the 
other hand, SHP-2 is generally considered as a positive signal transducer. Cells 
expressing a catalytically inactive cysteine-to-serine mutant of SHP-2 and those 
derived from SHP-2 knock-out mice show reduced activation of signal transduction 
pathways induced by growth factors and cytokine [78,97]. 
 
 
 
1.8 Aim of work  
 
The aim of this work is the study of the Bcr-Abl-independent signaling pathways 
involved in imatinib-resistance in chronic myeloid leukemia (CML) patients. To this 
aim, we have first used, as model system a couple of, Ima-sensitive (KCL22s) and 
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Ima-resistant (KCL22r) KCL22, CML cell lines. The Imatinib-resistant cell lines 
KCL22r and its sensitive counterpart KCL22s were established by Junia Melo and 
co-workers [55] to analyse primary Imatinib resistance in vitro. The parental cell line 
KCL22s is initially resistant to Imatinib and consist of sensitive and resistant 
subpopulations, witch can be isolated from the original cell line using 
methylcellulose. In KCL22r cells the resistance is innate and is not associated to 
mutations in the ATP-binding site of BCR/ABL or BCR/ABL overexpression [55]. 
Moreover, this cell couple exhibits same of the features typical of Ph+ CD34+/CD38-
/Lin- cells when exposed to Ima. Indeed, Ima exposure induces growth arrest but not 
apoptosis in KCL22s cells. Therefore, they represent an optimal in vitro system to 
analyse Imatinib resistance witch is based on a BCR/ABL-independent mechanisms. 
 
 
 
 
 
 
Fig.6. A. Illustration of potential signaling pathways controlled by Src homology 2 
(SH2) domain-containing protein tyrosine phosphatase 1 (SHP-1). SHP-1 plays an 
important role in the regulation of growth factor and cytokine signal transduction to 
modulate cell proliferation, differentiation, survival, and apoptosis. SHP-1 can 
regulate growth factor induced activation of phosphatidylinositol 3-kinase (PI 3-K)/Akt 
and nuclear factor-kappa B (NF-κB). SHP-1 may either negatively or positively 
regulate the activation of the extracellular signal-related kinases (ERKs) and the c-
Jun-amino terminal kinases (JNKs). In addition, SHP-1 can bind to the erythropoietin 
(EPO) receptor via its SH2 domain and modulate EPO activation of the Janus kinase 
2 (Jak2)/signal transducer and activator of transcription (STAT). B. Illustration of 
potential signaling pathways controlled by Src homology 2 (SH2) domain-containing 
protein tyrosine phosphatase 2 (SHP-2). Similar to SHP-1, SHP-2 has a critical role 
in a host of cellular signal transduction pathways that involve cell proliferation, 
differentiation, survival, and apoptosis. Through the association with Grb2-associated 
binder-1 (Gab1), a docking protein containing an N-terminal pleckstrin homology 
domain and several proline-rich SH3 domain-binding sequences, SHP-2 promotes 
growth factor induced activation of phosphatidylinositol 3-kinase (PI 3-K)/Akt, the 
extracellular signal-related kinases (ERKs), and nuclear factor-kappa B (NF-κB). 
A B 
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SHP-2 can either negatively or positively regulate the activation of Janus kinase 2 
(Jak2)/signal transducer and activator of transcription (STAT) and the c-Jun-amino 
terminal kinases (JNKs) depending on different circumstances. 
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2 Materials and methods 
 
2.1 Drug 
 
STI571 was kindly provided by Novartis Pharma (Basel, Switzerland). A 10 mM 
stock solution was prepared by dissolving the compound in sterile phosphate-
buffered saline (PBS) or dimethylsulfoxide (DMSO).  
 
2.2 Cell lines 
 
The K562 and KCL22s cells (5x105 cells/mL) were grown in RPMI 1640 medium 
(Gibco, Paisley, UK) supplemented with 10% fetal bovine serum (FBS) and 1 mM L-
glutamine, 100 U/ml penicillin, and 50 µg/ml streptomycin (herein referred to as RP-
10) in a humidified 95% O2 and 5% CO2 atmosphere at 37°C. For KCL22r  imatinib-
resistant cell line, we used same conditions but the media was further supplemented 
with 1µM Imatinib. This cell line has been supplied from professor Junia V. Melo of 
the Department of Haematology, Imperial College School of Science, Technology 
and Medicine, Hammersmith Hospital, London, UK. 
 
2.3 DNA and RNA extraction  
 
Mononuclear cells were isolated from BM aspirates by density gradient 
centrifugation, according to standard procedures. High-molecular-weight genomic 
DNA was performed with a commercially available kit (QIAamp DNA, Qiagen, Milan, 
Italy). Total RNA was extracted using the RNeasy kit (Qiagen, Milan, Italy) and 
treated with RNase-free DNase (Qiagen), according to the manifacturer direction.  
 
2.4 Methylation-Specific Polymerase Chain Reaction (MSP)   
 
The methylation-specific polymerase chain reaction (MSP) for promoter methylation 
was performed as described [104-105]. Briefly, treatment of DNA with bisulfite (which 
resulted in conversion of unmethylated cytosine to uracil, but unaffecting methylated 
cytosine) was performed with a commercially available kit (EpiTect Bisulfite Kit, 
Qiagen,Milan,Italy). MSP primers were designed to amplify the methylated (M-MSP) 
and unmethylated (U-MSP) alleles. Primers for PTPN6 were: 5'-GTG AAT GTT ATT 
ATA GTA TAG TGT-3' (forward) and 5'-TTC ACA CAT ACA AAC CCA AAC AAT-3' 
(reverse) for the unmethylated reaction; 5'-GAA CGT TAT TAT AGT ATA GCG TTC-
3' (forward) and 5'-TCA CGC ATA CGA ACC CAA ACG-3' (reverse) for the 
methylated reaction [88]. The annealing temperature for unmethylated reactions was 
59°C and for methylated reaction was 60°C. All MSP reactions were performed with 
positive and negative controls for both unmethylated and methylated alleles. DNA 
from normal samples was used as negative control, and methylated DNA 
(CpGenome Universal Methylated DNA; Intergen) was used as positive control. 
Control experiments without DNA were performed for each set of PCR. 
 
2.5 DNA sequencing  
 
The identity of the methylated and unmethylated sequences was confirmed by 
automated DNA sequencing. PCR products were gel purified, sequenced 
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bidirectionally, and analyzed on an automated DNA sequence analyser (3730 ABI 
Prism; Applied Biosystems).  
 
 2.6 5-Azacytidine (5-AC) treatment of the Leukemic Kcl22 cell lines 
 
The human leukemic cell lines Kcl22s/r  were seeded in 25 cm2 culture flasks at a 
density of 5*105/mL and treated with 1-2 µM 5-AC (Sigma, St Louis, MO) for 5 days, 
with fresh medium containing 5-AC replenished on day 2. Kcl22s/r cells were 
harvested every day  for genomic DNA, total cellular RNA, and whole cell protein 
extractions.  
 
2.7 Reverse transcription polymerase chain reaction (RT-PCR)  
 
One microgram of total RNA extracted from the patient samples or cell lines, was 
pre-warmed for 10 minutes at 70 °C;  the RNA solution was then incubated for 
10 min at 25 °C, 45 min at 42 °C and 3 min at 99 °C in a 20 µL reaction mixture 
containing 10 mM Tris–HCl (pH 8.3), 50 mM KCl, 5.5 mM MgCl2, 1 mM of each 
deoxyribonucleotide, 20 U of RNAsin (Pharmacia, Upsala, Sweeden), 25 mM 
random examers (Pharmacia), 10 mM of DTT (Pharmacia), and 100 U of MoMLV 
reverse transcriptase (Invitrogen).PCR amplification of SHP-1 and SHP-2 encoding 
cDNAs were separately carried out in a reaction mixture consisting of 1 × Master Mix 
(Applied BioSystem, Foster City, CA USA), 300 nM of the appropriate primer pair 
and 200 nM of the appropriate probe in a final volume of 25 µL using the following 
time/temperature profile: 95 °C, 15 s, and 60 °C, 1 min, for 50 cycles. All 
amplification reactions were carried out in triplicate. The primers and probes 
sequences were as follows: SHP1: 139bp; Forward: 
CGAGGTGTCCACGGTAGCTT, Reverse:CCCCTCCATACAGGTCATAGAAAT, 
Probe: Fam-TGACCCATATTCGGATCCAGAACTCAGG-Tamra; SHP2: were 
purchased assay on the made (Applied BioSystem, Foster City, CA USA). ABL was 
used as an internal control. SHP1 and SHP2 mRNA was normalized to ABL to 
obtain the relative threshold cycle (∆CT) and then related to the  ∆CT of normal 
cases to obtain the relative expression level (2-∆CT). All reaction were performed 
using an ABI-7900 sequence detector (Applied BioSystem, Foster City, CA USA). 
 
2.8 SHP1 and SHP2  shRNA  
 
To knock-down of SHP1 and SHP2 we used a vector that direct the transcription of a 
short-hairpin RNA (shRNA). In particular, shRNAs transcribed by RNA polymerase 
III (Pol III) promoters can trigger sequence-selective gene silencing in culture and in 
vivo. The vectors shSHP1, shSHP2 as well as a shRNA Non-silencing (NS) control 
vector were purchased from Open Biosystem  (Huntville, AL, USA) as glycerol 
stocks of transformed E. coli. The base vector for both plasmids is a retroviral pShag 
Magic version 2 (pSM2). The pSM2-SHP1 and pSM2-SHP2 are designed for high 
level expression of shRNA for the human SHP1 and SHP2 under the control of  the 
mouse U6 promoter. The pSM2-NS represents a negative control shRNA vector. E. 
coli were grown according to the manufacturer`s recommended protocols. The 
plasmids were purified using the Plasmid  kit (Qiagen, Milan, Italy), according to the 
manifacturer direction. The sequence of the shRNA insert was confirmed using a 
primer developed for the U6 promoter region ( 5` TGT GGA AAG GAC GAA ACA 
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CC 3`). Sequence analysis was performed using an automated DNA sequence 
analyser (3730 ABI Prism; Applied Biosystems).  
 
 
 
2.9 Cell transfection 
 
We seeded 5x105 KCL22 cells in 500 µl of growth medium with serum but without 
antibiotics, in a  well of a 24-well plates and transfected them 24 h later with 1 µg for 
well of the appropriate plasmid. The transfections were performed with 
Lipofectamine 2000 (Invitrogen, Carlsbad, USA) in accordance with the 
manufacturer's protocols. We determined transfection efficiency by parallel 
transfection of a GFP-expressing plasmid and assayed the percentage of 
fluorescent cells by flow cytometry. Forty-eight hours after transfection we selected 
for stably transfected cells. We transferred the transfected cells to medium 
containing puromycin (1µg/mL) for 2 days. For analysis of target gene mRNA knock-
down, we collected stably transfectes cells lysates and prepared total RNA. 
Expression of SHP1 and SHP2 (mRNA and Proteins) was monitored by real time 
and western blot. 
 
2.10 Cell viability assay  
 
Cells were plated at a density of 5 × 105 cells/mL in RP-10 with or without the 
inhibitor. Aliquots were taken out at 24-hour intervals for assessment of cell viability 
by trypan blue exclusion. 
 
2.11 Immunoblotting and immunoprecipitation analysis 
 
Cell lines were washed with cold phosphate-buffered saline three times. They were 
incubated with cold lysis buffer, 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1mM NaF, 1 
mM PMSF, 1% Nonidet P-40, 1mM EDTA, 1mM sodium orthovandate, Protease 
inhibitor cocktail (Complete mini EDTA-free Roche Applied Science) for 30 min and 
then cleared by centrifugation at 15,000xg for 20 min at 4°C. Protein concentration 
was measured by using the 2-D Quant kit (GE Healthcare). For immunoblot analysis 
KCL22r  and KCL22s protein extracts (20 µg) were resolved on a 10% SDS-PAGE 
gel and than transferred onto nitrocellulose membrane (GE Healthcare). The 
membrane was blocked in 5% non-fat milk in PBS for 2 h and incubated with 1% 
milk/PBS1X /0,05% TWEEN  containing a monoclonal antibody against SHP2 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) used at a diluition of 1:500 or a 
polyclonal antibody against SHP1 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) used at a diluition of 1:500. An anti-GAPDH antibody was used as control, at a 
diluition of 1:1000. Immunoblot detections were carried out using HRP-conjugated 
anti-rabbit or anti–mouse secondary antibodies (Ge Healthcare) used  respectively 
at a diluition of 1:10000 and 1:5000. Detection was made by using the ECL-Advance 
Western Blotting Detection kit (GE Healthcare) by chemioluminescence. The 
resulting western blot image were scanned and analyzed by PDquest 7.1 software 
(Biorad). Protein bands were defined , background was substracted and volumes 
were measured. Band volumes were normalized by using actin as control, visualized 
on the same membrane. For immunoprecipitation assays, cell lysates (500 µg) were 
precleaned with the appropriate control, normal mouse or rabbit IgG (Santa Cruz 
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Biotechnology, Santa Cruz, CA, USA), corresponding to the host species of the 
primary antibody used for the immunoprecipitation, for 2h at 4°C and then incubated 
with a resuspended volume of Protein A/G-PLUS-Agarose beads (Santa Cruz 
Biothecnology Santa Cruz, CA, USA) for 1h at 4°C. Beads were then centrifugated 
at 8000xg for 5 min at 4°C. The supernatant was incubated with primary polyclonal 
antibodies (20 ul) of  anti–SHP1 or anti–SHP2 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) overnight at 4°C and then incubated with a fresh volume of Protein 
A/G-PLUS-Agarose beads for 5h at 4°C. Beads were then centrifugated at 8000xg 
for 5 min at 4°C. After extensive washing of the pellet beads with IP buffer (Tris-HCl 
50 mM pH 7.5, NaCl 150 mM, NaF 1mM, PMSF 1 mM, Nonidet P-40 1%, 1mM 
EDTA, 1mM sodium orthovandate, Protease inhibitor cocktail (Complete mini EDTA-
free Roche Applied Science) the resulting immune complexes were eluted from the 
beads with 2X electrophoresis sample buffer at 90°C for 10 min. The supernatants 
were then separated by electrophoresis in 10% SDS/polyacrylammide gels and then 
transferred to nitrocellulose paper for immunoblotting analysis, performed as 
described above. 
 
2.12 Cell Cycle Analysis 
 
Cells were washed once in PBS then incubated for 15 min with the DNA binding 
dyes propidium iodure (10 µg/ml,Immunotech SA, France). Thereafter, the cells 
were analysed by flow cytometry using forward and side scattering to exclude any 
cell debris of the analysis. The percentage of apoptotic cells was determined in the 
hypodiploid peak resulting of PI fluorescence. 
 
2.13 Proliferation assay 
 
Cells were plated at a density of 5 × 105 cells/mL in RP-10 with or without the drug. 
The proliferation  was assayed by incubation with 10 µM bromodeossiuridine (BrdU) 
(Becton Dickinson, USA) for 30 min at 37°C; cells were then treated with 0.5% 
Tween 20 (Merck) centrifuged at 2000 rpm for 5 min, resuspended in 0.5 ml 0.5% 
Tween 20 in PBS and in 0.5 ml 4 N HCl and incubated for 30 min at room 
temperature. After centrifugation, cells were suspended in 1 ml 0.1 M Borax (Riedel-
de Haen), centrifuged, incubated for 1 h at 4°C in 200 µl 0.5% Tween 20 in PBS 
containing 5 µl anti-BrdU monoclonal antibody (Becton Dickinson, USA), centrifuged, 
incubated for 30 min at 4°C in 200 µl 0.5% Tween 20 in PBS and 5 µl of fluorescein 
isothiocyanate (FITC)-labeled goat anti-mouse immunoglobulins (Becton Dickinson, 
USA), centrifuged, incubated for 15–30 min at 4°C in 200 µl 0.5% Tween 20 in PBS 
and in 200 µl propidium iodide (Sigma) and finally analyzed on a fluorescence 
activated cell sorter FACScan (Becton Dickinson, USA). 
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3 Results and Discussion 
Although rare in chronic phase myeloid leukemia (CML), primary or acquired 
resistance to the treatment with tyrosine kinase inhibitors (TKI) may be observed in 
the advanced phases of disease. Bcr/Abl related resistance has been well 
described, while the other mechanisms of resistance are poorly understood. In this 
study, we investigated the role of two SH2-containing, non-receptor protein tyrosine 
phosphatases (Shp1 and Shp2) in the resistance to Imatinib (Ima). To this aim, we 
have first used, as model system, a couple of Ima-sensitive (KCL22s) and Ima-
resistant (KCL22r) KCL22, CML cell lines. The Imatinib-resistant cell lines KCL22r 
and its sensitive counterpart KCL22s were established by Junia Melo and co-
workers [55] to analyse primary Imatinib resistance in vitro. The parental cell line 
KCL22s is initially resistant to Imatinib and consist of sensitive and resistant 
subpopulations, witch can be isolated from the original cell line using 
methylcellulose. In KCL22r cells the resistance is innate and is not associated to 
mutations in the ATP-binding site of BCR/ABL or BCR/ABL overexpression [55]. 
Moreover, this cell couple exhibits some of the typical features of Ph+ CD34+/CD38-
/Lin- cells when exposed to Ima. Indeed, Ima exposure induces growth arrest but not 
apoptosis in KCL22s cells. Therefore, they represent an optimal in vitro system to 
analyse Imatinib resistance witch is based on a BCR/ABL-independent mechanisms. 
In particular, in this study, we investigate the role of two SH2-containing, non-
receptor protein tyrosine phosphatases (Shp1 and Shp2) in the resistance to Imatinib 
(Ima). In a preliminary evaluation, using in parallel both a microarray and a 
proteomic approach, we found that the cell lines examined had a great divergence in 
SHP-1 expression and that SHP-1 was down-regulated in resistant KCL22r cell line. 
Real time PCR and western blot analysis, confirmed a very low level of Src 
homology 2 domain-containing tyrosine phosphatases SHP-1 (both mRNA and 
protein), a protein with a tumour suppressor activity, in the KCL22r resistant cells, 
when compared to KCL22s sensitive cells (Fig.7). While, SHP-2 seems to be equally 
expressed between two cell lines (both mRNA and protein),(Fig.7). 
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Fig.7. A Levels of SHP-1 and SHP-2 mRNA in KCL22 cell lines performed by real 
time PCR. All experiment were performed in triplicate and results were indicate as 
mean±SD. B. Western blot analysis on total protein lysates of KCL22r cells and 
KCL22s cells. Proteins were separated on 10% SDS-PAGE and immunoblotted 
respectively with antibodies against SHP2 and SHP1 proteins GAPDH was used as 
control. 
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SHP-1 is highly expressed in hematopoietic cells and, at a lower level, in various 
nonhematopoietic cells [26]. In humans, reduction of SHP-1 gene expression is 
observed in natural killer cell lymphomas as well as other types of 
lymphomas/leukemias [82-83]. Decreased expression level of SHP-1 seems to be 
associated with progression of Chronic myeloid leukaemia (CML) [85]. Moreover, 
Shp1 was shown to be physically associated with Bcr-Abl with evidence supporting 
their functional interaction [86-87].  More recent studies showed that Shp1 protein 
and mRNA are absent in the CML blast cell line K562 [87-88], whereas 
differentiation of K562 cells was associated with Shp1 expression [87]. Furthermore, 
overexpression of Shp1 blocks transformation by Bcr-Abl [89]. These observations 
indicate that Shp1 might plays a significant role in the negative regulation of Bcr-Abl 
and that lack of Shp1 is important for CML transformation. To identify the reason of 
the SHP-1 down-regulation in KCL22r cell line we approached a methylation-specific 
PCR (MSP) analysis on SHP-1 promoter. This analysis showed that the down-
regulation of this gene is related to the methylation level of its promoter. In fact, only 
KCL22r showed the SHP-1 promoter methylated respect to KCL22s cell line (Fig.8). 
The identity of the methylated and unmethylated sequences was confirmed by 
automated DNA sequencing (Fig.9).  
 
 
 
 
 
Fig.8 Methylation-specific polymerase chain reaction (MSP) of KCL22 cell 
lines.  MSP for SHP1 showing that SHP1 Methylation is present in KCL22r and 
absent in KCL22s. B indicates blank; P, positive control; U, Unmethylated allele; M, 
Methylated allele; MW molecular weight.  
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Fig.9 Sequencing of MSP SHP1. (A) Sequencing of M-MSP SHP1 in bisulfite 
converted KCL22r. The DNA sequence of the “methylated” Me PCR product was 
aligned and compared with the germ line sequence of the wild-type DNA (Wt). 
Methylated cytosine residues in CpG dinucleotide remained as C, whereas 
unmethylated cytosine read as T after bisulfite conversion. (B) Sequencing of U-
MSP SHP1 in bisulfite converted KCL22s. The DNA sequence of the “unmethylated” 
Ue PCR product was aligned and compared with the germ line sequence of the wild-
type DNA (Wt). 
DNA methylation, catalyzed by DNA methyltransferase, involves the addition of a 
methyl group to the carbon 5 position of the cytosine ring in the CpG dinucleotide, 
leading to a conversion to methylcytosine. In many cancers, the CpG islands of 
selected genes are aberrantly methylated (hypermethylated), resulting in 
transcriptional repression of these genes. This may serve as an alternative 
epigenetic mechanism of gene inactivation. DNA methylation has been thought to be 
one of the important mechanisms of gene silencing and development of cancer. 
Some studies revealed that reduced expression of the SHP-1 gene in various types 
of leukemias, multiple myeloma and lymphomas mainly occurred by promoter 
methylation [88, 98].  To study the biologic significance of SHP-1 methylation, we 
treated the KCL22 cell lines with a DNA methyltransferase inhibitor 5-aza-2'-
deoxycytidine (5-AC) that induces DNA demethylation and re-expression of 
epigenetically silenced genes. Treatment with 5-AC led to a progressive 
demethylation of SHP-1 in KCL22r that started from day 2 onward, as shown by 
positive U-MSP with increasing amplification intensity (Fig.10). The progressive 
demethylation of SHP-1 was associated with a parallel re-expression of SHP-1 
mRNA and protein (Fig.10). Interestingly, the re-expression of Shp1 resulted in a 
corresponding down-regulation of phosphorylated STAT3 and Erk1/2 (Fig.10), two 
important signal mediator involved in proliferation and differentiation of myeloid 
lineage. The level of nonphosphorylated STAT3 and Erk1/2 remained unchanged, 
showing that SHP-1 re-expression interfered with phosphorylation of STAT3 and 
Erk1/2. In sensitive KCL22s cell line treated with 5-AC, we didn`t find variations in 
the same molecular pathway after treatment (Fig.10). Therefore, the biologic 
consequence of SHP-1 gene methylation in KCL22r, was repression of SHP1 
expression and, hence, unopposed STAT3 and Erk1/2 phosphorylation. On the other 
hand, demethylation leading to re-expression of SHP-1 resulted in down-regulation 
of phosphorylation of STAT3 and Erk1/2. These results implied that the epigenetic 
control of SHP-1 expression might be critically involved in the regulation of STAT3 
and Erk1/2 phosphorylation in KCL22r cell line. The proliferation and cell cycle of the 
same cell lines, exposed to 1 and 2 µmol/L 5-AC, have been analyzed by 
bromodeossiuridine (BrdU) and propidium iodide (PI) assay to evaluate the effects of 
the SHP-1 re-expression in resistant KCL22r cell line. In particular, KCL22 cell lines 
were exposed to 1 or 2 µM 5-AC for 4 days. Everyday we collected and harvested 
cell aliquots that were treated with PI or BrdU as described in materials and 
methods. After all samples were analyzed by flow cytometry. The results, showed 
that the 5-AC treatment reduces the proliferation capacity both KCL22s and KCL22r 
cell lines. Moreover, we found a increase percentage of cells in G0/G1 phase only in 
resistant KCL22r cell line (Fig.11).  
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Fig.10. 5-Azacytidine (5-AC) treatment of the KCL22r and KCL22s cell lines. 
The KCL22r cell line was totally methylated at SHP1, as shown by positive 
amplification only in M-MSP and not U-MSP at day 0 (T0) before treatment with 5-
AC. On treatment with 5-AC, positive amplification appeared in U-MSP on day 2 
(T2), indicating SHP1 demethylation. The progressive demethylation of SHP1 was 
associated with increasing re-expression of SHP1, as shown by Real time PCR and 
Western blot. Following treatment we observed an increase in the expression of 
SHP-1 in KCL22 resistant cell line. This data supports the hypothesis that SHP-1 
promoter hypermethylation is related to the down-regulation of SHP-1 in resistant 
cell line. In addiction we observed a reduction of pSTAT3 and pERK1/2 expression 
in KCL22 resistant cell line in contrast of KCL22 sensitive cell line. Comparable 
protein loading was shown by GAPDH.  MW indicates molecular weight marker; B, 
blank; TO to T4, days 1 to 4 after 5-AC treatment; NC, normal control; PC, positive 
control with methylated DNA.  
Therefore, 5-AC treatment confirm that aberrant hypermethylation of SHP-1 
promoter lead to a decreased of its expression in KCL22r cell line and this assets 
proliferation and survival alternative pathway, BCR-ABL independent, as JAK-
STATs and MAPKs. Subsequently, we found the SHP-1 binding proteins. By 
immunoprecipitation and western blot analysis we found the interaction of SHP-1 
with another Src homology 2 domain-containing tyrosine phosphatases SHP-2 only 
in sensitive KCL22s but not in resistant KCL22r cell line that showed also low level 
of SHP-1 (Fig.12). As control we analyzed the SHP-1 binding proteins also in the 
K562 CML cell line that is sensitive to Imatinib treatment and also in this case we 
found the interaction between SHP-1 and SHP-2.  Previous experiments of real time 
PCR and western blot, showed that SHP-2 is equally expressed in sensitive and 
resistant KCL22 cell lines (Fig.7). It has been well accepted that signal transduction 
is carried through formation of multiple signaling complexes.  
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Fig.11. A Proliferation assay by BrdU test on KCL22 cell lines exposed to 1 µmol/L 
5-AC for 4 days  B. Cell cycle assay by (PI) assay on KCL22 cell lines exposed to 1 
µmol/L 5-AC for 4 days. As control we used untreated cell lines. 
 
 
 
 
 
 
 
 
Fig.12. KCL22 sensitive (A) and resistant (B) cellular extracts were 
immunoprecipitated (IP) with anti-SHP1 antibody and the immunoprecipitates were 
subjected to Western blotting analyses with an anti-SHP2 antibody as indicated. 
K562 (C) cellular extracts were immunoprecipitated (IP) with anti-SHP1 antibody and 
the immunoprecipitates were subjected to Western blotting analyses with an anti-
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SHP1 antibody as indicated. An irrelevant rabbit IgG was used as control. IN = input, 
IP = immunoprecipitate, C = control. 
This is particularly true for SHP-1 and SHP-2 because both enzymes stay largely 
inactive in cytosol because of their internal suppressed structures [99-100]. 
Furthermore, SHP-1, and SHP-2 formed a signaling complex with GAB1, and SHP-1 
and SHP-2 interact with each other in colorectal adenocarcinoma Caco-2 cell line, 
but the functional role of this interaction in growth factor signaling is still unknown 
[101]. In order, to understand if the down-regulation of SHP-1 and its interaction with 
SHP-2 could be involved in KCL22 Imatinib resistance we approached other 
functional analysis. We used the RNA interference technique, that has been widely 
used to study the loss-of-function phenotype of genes, to knock down the expression 
of SHP-1 in sensitive KCL22s and SHP-2 in resistant KCL22r cell lines. For this 
reason we employed commercially available short hairpin RNA (shRNA). Using 
Lipofectamine 2000 (Invitrogen) as described in materials and methods, we 
transfected KCL22r cell line with a specific retroviral plasmid containing a specific 
sequence that originates a small hairpin RNA (ShRNA) that interfering SHP-2 
expression. We done the same way in KCL22s but in this case we interfering SHP-1 
expression. As control we transfected the cell lines with a empty plasmid. Results 
are shown in (Fig.13) SHP-1 shRNA specifically suppressed the expression of SHP-
1 in KCL22s by 70% but had no effect on that of SHP-2. Conversely, the shRNA of 
SHP-2 specifically knocked down the expression of SHP-2 in KCL22r by 75% but left 
SHP-1 intact. We also examined the protein levels of GAPDH to confirm that they 
were not affected by the siRNAs. The data suggest that these shRNAs worked very 
efficiently to suppress the expression of SHP-1 and SHP-2. This provides an 
excellent system to study the function of these enzymes in KCL22 Imatinib 
resistance. We employed phospho-specific antibodies to determine the activation of 
ERK1/2 and STAT3 in knockdown SHP-2 KCL22r cells. As shown in (Fig.13), 
knockdown of SHP-2 in KCL22r cells significantly reduced the activation of ERK1/2 
and STAT3 . The magnitude of ERK1/2 activation was reduced by about 80% and 
STAT3 by about 70%. These data are very similar to those observed with cells 
overexpressing dominant negative mutants of SHP-2 [102-103].  
 
 
 
 
 
 
 
Fig. 13. Effects of knockdown of SHP1 on KCL22s and SHP2 on KCL22r by shRNA. 
The cell lines were transfected with the indicated ShRNA in the presence of 
Lipofectamine 2000 as described under “Materials and methods“. Cell extracts were 
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subjected to western blot analysis with specific antibodies to detect the indicated 
proteins. KD = Knockdown, Control= Cell line transfected with plasmid empty as 
described in materials and methods. 
It is now well accepted that the critical role of SHP-2 in development is due to its 
ability to promote Ras/MAPK stimulation in response to diverse agonists. Ras/MAPK 
is a major signalling cascade mobilized by a broad range of membrane receptors to 
modulate cell fate (proliferation, differentiation), notably in response to growth 
factors. Abundant genetic and biochemical evidence demonstrate that Shp2 has a 
positive (signal-enhancing) action on this pathway [96]. For example, in cells with 
inactivated SHP-2, MAPK activation induced by EGF, PDGF or FGF is lower, or at 
least less sustained, than in normal cells. Similarly, overexpression of a catalytically 
inactive form of Shp2 exerts a strong dominant negative effect on Ras/MAPK 
stimulation in a number of different cellular models [96]. In the same way, 
knockdown SHP-2 KCL22r cells treated with Imatinib 1µmol/L showed a greater 
sensibility to treatment. To compare the cell viability respect to imatinib treatment 
between knockdown SHP-2 KCL22r and KCL22r control cells, trypan blue exclusion 
assay were performed on the same cells treated with Imatinib 1µmol/L for 4 days. 
The results in Fig.14. showed after 4 days of treatment, a 50% decrease of cell 
viability in knockdown SHP-2 KCL22r respect to KCL22r control. Knockdown of 
SHP-2 in KCL22r seems restore the imatinib sensitivity in these cells. Knockdown of 
SHP-1 in KCL22s cells increased the activation of ERK1/2 and STAT3. The 
magnitude of ERK1/2 activation was increased by about 40% and STAT3 by about 
50% (Fig.13). In addition, knockdown SHP-1 KCL22s cells treated with Imatinib 
1µmol/L showed reduced sensitivity to the treatment. The results in fig.14. after 4 
days of treatment showed an higher percentage of 25% of cell viability in knockdown 
SHP-1. Knockdown of SHP-1 in KCL22s seems increase the imatinib resistance in 
these cells. This data confirm that SHP-1 and SHP-2 might be implicated in Imatinib 
response. Experiments with knockdown SHP1 and 2 seems moreover show that 
SHP-1 might be implicated in negative control of SHP-2. Therefore, a deregulated 
balance between the expression levels of Shp1 and 2 in resistant KCL22 cell line 
may account for the Bcr-Abl independent activation of alternative pathway as 
Ras/MAPKs, JAK/STATs and for the resistance to Imatinib of these cells. The data 
obtained in KCL22 model system were next translated in patients. By real time PCR 
we misured the expression levels of SHP-1 and SHP-2 in bone marrow of 60 
patients with CML at base line. Patients were divided into three different subgroups 
on the basis of their response to imatinib treatment at 18 months (Tab.1) according 
to the European Leukemia Net (ELN) criteria.  We analysed 35 optimal, 17 
suboptimal and 8 failure responder to Imatinib treatment. The levels of SHP-1 mRNA 
were significantly more high in optimal responders [ratio of SHP1/ABL 5.8±1.77, 
(mean±SD)] when compared to the suboptimal (3.8±1.3, *p=0.001) and failure 
(3.2±1.04, *p=0.002) (Fig.15). As control we analysed also SHP-1 mRNA in 21 Ph-
negative chronic myeloproliferative disorders (CMDP), JAK2 wild type (ratio of 
SHP1/ABL 6.0±2.2, *p=0.6). Therefore, our data showed that imatinib resistance 
patients have low levels of SHP-1 respect to the imatinib sensitive and CMDP 
patients. With the same methods we analyzed also SHP-1 expression in CD34+ 
cells, selected by cell sorting, as described in materials and methods, from 6 optimal 
[ratio of SHP1/ABL 1.7±0.25, (mean±SD)]  and 6 failure responders [ratio of 
SHP1/ABL 0.9±0.15, (mean±SD) *p=0.017]  (Fig.16).  In this case, we analyzed as 
controls 3 CMDP samples [ratio of SHP1/ABL 2,5±0.25, (mean±SD)]   and 3 normal 
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samples [ratio of SHP1/ABL 2,1±0.22, (mean±SD)]. Therefore, also in CD34+ cells 
isolated from patients with CML, we found a statistically significative differences 
between failure and optimal responders patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.14. A. Cell viability assessed by trypan blue exclusion of Knockdown SHP-2 
KCL22r cell line respect to KCL22r control. All experiment were performed in 
triplicate and results were expressed as means±SD. B. Cell viability assessed by 
trypan blue exclusion of Knockdown SHP-1 KCL22s cell line respect to KCL22s 
control. All experiment were performed in triplicate and results were expressed as 
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means±SD. KD= knockdown, Control= Control= Cell line transfected with plasmid 
empty as described in materials and methods. 
 
 
 
 
 
Fig 15. Levels of SHP1 mRNA in bone marrow of CML patients at base line. CML 
patients were classified, according to the ENL definitions and compared with CMDP. 
Dotted lines indicate median values of the four groups. Statistical analysis performed 
by Tukey`s multiple comparison test revealed a significant difference in SHP1 
expression between optimal responder and both suboptimal (*p<0.001) and failure 
responder (*p<0.002).   
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Fig.16. Levels of SHP1 mRNA  in CD34+ cells of CML patients at base line. CML 
patients were classified according to the ENL definitions and compared with CD34+ 
of CMDP patients and CD34+ of normal samples (NC). The results are shown as 
means±SD. .Statistical analysis performed by by Tukey`s multiple comparison test 
revealed a significant difference in SHP1 expression between optimal responder and 
failure responder (*p=0.017).   
In next step of this study we investigated also if the SHP-1 expression might have a 
predictive role in Imatinib treatment response. To this aim, we measured, by real time 
PCR, SHP-1 mRNA  levels in leukaemia cells isolated from peripheral blood of 48 
newly diagnosed CML patients enrolled into the TOPS (Tyrosine kinase inhibitor 
Optimization and Selectivity) trial. TOPS is a prospective, open-label, randomized 
(2:1) Phase III trial that compared Ima 800mg/d to 400mg/d in CP-CML. The findings 
end point of the trial is the rate of major molecular response (MMR) indicated by 
several reports as a parameter that predict a benefit for progression free survival 
(PFS). MMR can be defined as a 3 or more log-reduction of BCR-ABL/control gene 
ratio from a laboratory standardised baseline or an international scale converted 
BCR-ABL/control gene ratio of <0.1% [53]. Results indicate that the SHP1 mRNA 
levels is significantly different between those patients who do and do not achieved 
MMR by 12 months [ratio of SHP1/ABL 7.4 ± 3.8 vs 6.0 ± 3.7, mean±SD, *p = 0.017] 
(Tb.2). There is not statistical evidence that patients who achieved MMR earlier than 
12 months i.e. at 6 and 9 months, have different baseline levels of SHP1, however 
the data are suggestive of a difference which might become statistically significant 
with a larger sample size. Complete cytogenetic response, CCyR, was a secondary 
end point of the TOPS study. CCyR is the complete absence of leukemic (Ph+) cells 
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in the bone marrow of CML patients by either conventional or FISH cytogenetic 
testing. Overall, 65% have achieved CCyR by 6 months, and 85% by 12 months, and 
although not statistically different, results indicate that SHP1 levels tended to be 
higher in patients who obtained CCyR, and the our further study with a larger sample 
size will show if the differences might become significant. Therefore, SHP1 
expression may acts as predictor of MMR at 12 months. Statistical analysis have al 
shown that SHP-1 may be used as molecular marker for prediction of imatinib 
response (Fig.17).  
 
 n° Patients SHP-1/ABL 
Mean 
S.D. Median p-value* 
No MMR 27 5.0 3.2 4.3 
MMR 21 7.4 3.8 6.9 
0.017 
Total 48 6.0 3.7 5.3  
 
Tab. 2. Table of 48 TOPS patients analyzed for SHP-1 expression. Statistical 
analysis confirm a statistically significative variation between SHP-1 expression level 
of patients that by 12 months obtained Major Molecular Response (MMR) and those 
that at same time didn`t obtained Major molecular response (No MMR). SD = 
Standard deviation. * Test for difference in location by Wilcoxon rank-sum test 
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Fig. 17. ROC curve for SHP1 expression as a marker for MMR at 12 months. AUC = 
0.69 (0.54, 0.84). 
 
4 Conclusions 
To identify new Bcr-Abl-independent mechanisms involved in imatinib-resistance in 
chronic myeloid leukemia (CML) patients, we first analyzed as model system, a 
couple of Ima-sensitive (KCL22s) and Ima-resistant (KCL22r) KCL22 cell lines. In 
these cells, Ima resistance is independent by the oncogenic Bcr/Abl activity. 
Expression and proteomic analysis showed a very low level of Shp1 (both mRNA 
and protein), a protein with a tumour suppressor activity, in the KCL22r resistant 
cells, when compared to KCL22s sensitive cells. We have al shown the down-
regulation of this gene to be related to the methylation level of SHP1 promoter. 
Indeed, 5-Azacytidine (5-AC) treatment, along with demethylation of the promoter 
region, re-induced expression of SHP-1 in KCL22r. That treatment also re-
established the Ima sensitivity, i.e. Ima growth inhibition, in these cells. At molecular 
level, the restored Ima sensitivity was associated to a significant reduction of 
phosphorylation of both STAT3 and ERK1/2. Therefore, 5-AC treatment confirm that 
aberrant hypermethylation of SHP-1 promoter lead to a decreased of its expression 
in KCL22r cell line and this assets proliferation and survival alternative pathway, 
BCR-ABL independent, as JAK-STATs and MAPKs. We also found a interaction 
between SHP-1 and SHP-2 another SH2-containing, non-receptor protein tyrosine 
phosphatases, well known as positive regulator of oncogenic pathways, including the 
Ras/MAPK pathway. We found the interaction only in sensitive KCL22s but not in 
resistant KCL22r cell line that showed also low level of SHP-1 (Fig.12). SHP-1 and 
SHP-2 share over 55% sequence identity and are regulated by similar mechanisms. 
However, their biological functions seems to be quite different (Fig.6) [96]. In Ph+ 
cells, oncogenic Bcr/Abl protein activates Shp2 through Gab2, an adaptor protein 
that, once phosphorylated is able to bind SH2 domain of Shp2. Through complex 
interactions that may involve the two carboxy-terminal tyrosine residues (542 and 
580) Shp2 is also a signal transducer of growth factor receptor. We hypothesized 
that, SHP-1, through dephosphorylation, might modulate the activity of SHP-2 and 
constitute an important mechanism of Ima resistance. Knock-down of SHP-1 in 
KCL22s cell line resulted in increase phosphorylation of ERK1/2 and STAT3 and in 
its reduced sensitivity to the drug, thus supporting the role of this protein in Ima 
sensitivity. On the other hand, knock-down of SHP-2 in KCL22r, that shows low 
SHP-1 level, resulted in growth inhibition, restored Ima sensitivity and is associated 
to a significant reduction of phosphorylation of both STAT3 (60%) and ERK1/2 
(70%). The data on primary cells support the role of Shp1 in Ima resistance in 
patients. The levels of Shp-1 mRNA were significantly reduced in resistant patients 
[ratio of SHP1/ABL 3.2 ± 1.04, (mean±SD), *p<0.002] when compared to the 
suboptimal (3.8±1.54) and optimal  responders (5.8±1.77). Moreover, the SHP-1 
decrease was observed also in CD34+ cells isolated from 6 resistant patients in 
comparison to 6 optimal responders. In conclusion, our study suggests that an 
aberrant balance between the Shp1 and 2 levels play a role in the Bcr-Abl 
independent resistance to Ima through activation of Ras/MAPK pathway and that 
lower levels of Shp1 are associated with non responsive patients. Therefore, 
expression and statistical analysis on set of patients enrolled in TOPS trials showed 
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that SHP1 expression may acts as predictor of MMR at 12 months and that this 
gene might be used as a molecular marker to imatinib response.  
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